[go: up one dir, main page]

MD20170073A2 - Terapii combinate pentru tratarea cancerelor - Google Patents

Terapii combinate pentru tratarea cancerelor Download PDF

Info

Publication number
MD20170073A2
MD20170073A2 MDA20170073A MD20170073A MD20170073A2 MD 20170073 A2 MD20170073 A2 MD 20170073A2 MD A20170073 A MDA20170073 A MD A20170073A MD 20170073 A MD20170073 A MD 20170073A MD 20170073 A2 MD20170073 A2 MD 20170073A2
Authority
MD
Moldova
Prior art keywords
combination therapies
treating cancers
methods
entospletinib
navitoclax
Prior art date
Application number
MDA20170073A
Other languages
English (en)
Russian (ru)
Inventor
Паоло Джули А. Ди
Рэндалл Марк Джонс
Даниэль Б. ТУМАС
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55398445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20170073(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20170073A2 publication Critical patent/MD20170073A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la metode care se referă la o strategie terapeutică pentru tratamentul cancerului, inclusiv al tumorilor maligne hematologice. În particular, metodele includ administrarea entospletinibului şi a unui inhibitor al Bcl-2, cum ar fi venetoclax, navitoclax şi ABT-737.
MDA20170073A 2015-02-03 2016-01-29 Terapii combinate pentru tratarea cancerelor MD20170073A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111604P 2015-02-03 2015-02-03
PCT/US2016/015727 WO2016126552A1 (en) 2015-02-03 2016-01-29 Combination therapies for treating cancers

Publications (1)

Publication Number Publication Date
MD20170073A2 true MD20170073A2 (ro) 2018-02-28

Family

ID=55398445

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20170073A MD20170073A2 (ro) 2015-02-03 2016-01-29 Terapii combinate pentru tratarea cancerelor

Country Status (25)

Country Link
US (2) US20180117052A1 (ro)
EP (1) EP3253385A1 (ro)
JP (1) JP2018503653A (ro)
KR (1) KR20170104616A (ro)
CN (1) CN107205992A (ro)
AU (1) AU2016215643A1 (ro)
BR (1) BR112017016019A2 (ro)
CA (1) CA2974828A1 (ro)
CL (1) CL2017001943A1 (ro)
CO (1) CO2017007662A2 (ro)
CR (1) CR20170352A (ro)
CU (1) CU20170099A7 (ro)
EA (1) EA201791516A1 (ro)
EC (1) ECSP17048849A (ro)
GT (1) GT201700167A (ro)
IL (1) IL253573A0 (ro)
MA (1) MA41449A (ro)
MD (1) MD20170073A2 (ro)
MX (1) MX2017009724A (ro)
PE (1) PE20171241A1 (ro)
PH (1) PH12017550063A1 (ro)
SG (1) SG11201706107SA (ro)
SV (1) SV2017005489A (ro)
TW (1) TW201639573A (ro)
WO (1) WO2016126552A1 (ro)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
KR101717809B1 (ko) 2010-03-11 2017-03-17 질레드 코네티컷 인코포레이티드 이미다조피리딘 ｓｙｋ 억제제
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
KR101750667B1 (ko) 2013-07-31 2017-07-04 길리애드 사이언시즈, 인코포레이티드 Syk 억제제
CA2932726C (en) 2013-12-04 2019-06-04 Gilead Sciences, Inc. Methods for treating cancers with entospletinib
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3036384A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
US10759798B2 (en) * 2016-09-14 2020-09-01 Hangzhou Solipharma Co., Ltd. ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof
MX2019012660A (es) * 2017-04-28 2020-07-27 Actinium Pharmaceuticals Inc Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa.
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
SG11202005985PA (en) 2018-01-10 2020-07-29 Recurium Ip Holdings Llc Benzamide compounds
CN113950479A (zh) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 作为syk抑制剂的缩合吡嗪的固体形式
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CA3214527A1 (en) * 2021-04-05 2022-10-13 Doo-Young Jung Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
BRPI0922225B1 (pt) * 2008-12-08 2022-01-11 Gilead Connecticut, Inc. Inibidores de syk imidazopirazina, composição farmacêutica, e uso do composto
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
JP2013505249A (ja) 2009-09-20 2013-02-14 アボット・ラボラトリーズ Ｂｃｌ−２タンパク質関連疾患の治療における使用のためのＡＢＴ−２６３結晶形態および溶媒和物
EP2531217A4 (en) 2010-02-04 2013-11-27 Gilead Biologics Inc ANTIBODIES THAT BIND TO LOXL2 (LYSYL OXIDASE-LIKE 2) AND METHODS OF USE THEREOF
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
KR101827048B1 (ko) 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
EP2749572A4 (en) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
GB201115529D0 (en) 2011-09-08 2011-10-26 Imp Innovations Ltd Antibodies, uses and methods
WO2013052699A2 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
JP2015529195A (ja) * 2012-08-14 2015-10-05 ギリアード カリストガ エルエルシー 癌を処置するための組合せ治療
CN111481552A (zh) * 2012-09-07 2020-08-04 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
AR092662A1 (es) 2012-09-24 2015-04-29 Gilead Sciences Inc Anticuerpos anti-ddr1
JP6125663B2 (ja) 2012-12-21 2017-05-10 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
NZ714710A (en) 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
AU2014296308C1 (en) 2013-07-30 2018-09-13 Kronos Bio, Inc. Polymorph of Syk inhibitors
UA115815C2 (uk) * 2013-07-30 2017-12-26 Гіліад Коннектікут, Інк. Склад на основі інгібіторів syk

Also Published As

Publication number Publication date
CL2017001943A1 (es) 2018-03-02
US20160220573A1 (en) 2016-08-04
ECSP17048849A (es) 2017-10-31
MA41449A (fr) 2017-12-12
WO2016126552A1 (en) 2016-08-11
MX2017009724A (es) 2017-11-17
PE20171241A1 (es) 2017-08-24
US20180117052A1 (en) 2018-05-03
CR20170352A (es) 2017-09-29
EP3253385A1 (en) 2017-12-13
IL253573A0 (en) 2017-09-28
SV2017005489A (es) 2017-10-17
CO2017007662A2 (es) 2017-10-20
CN107205992A (zh) 2017-09-26
CU20170099A7 (es) 2018-03-13
EA201791516A1 (ru) 2018-01-31
AU2016215643A1 (en) 2017-08-10
GT201700167A (es) 2017-11-02
SG11201706107SA (en) 2017-08-30
PH12017550063A1 (en) 2018-02-05
KR20170104616A (ko) 2017-09-15
BR112017016019A2 (pt) 2018-03-20
CA2974828A1 (en) 2016-08-11
TW201639573A (zh) 2016-11-16
JP2018503653A (ja) 2018-02-08

Similar Documents

Publication Publication Date Title
PH12017550063A1 (en) Combination therapies for treating cancers
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
IN2014MU00303A (ro)
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2016008304A (es) Usos de oligouronatos en el tratamiento de cancer.
PH12016501838A1 (en) Compounds and their methods of use
HK1255939A1 (zh) 用於治疗癌症之组合疗法
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
HUE063428T2 (hu) PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
HK1259026A1 (zh) 用於治疗癌症的抗趋除剂的局部递送
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
EA201691846A1 (ru) Композиции и способы лечения рака печени
MX2019003002A (es) Terapias de combinacion que usan derivados de indazolilbenzamida para el tratamiento del cancer.

Legal Events

Date Code Title Description
FC9A Refusal of application (patent for invention)